Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers
B Bresnihan, E Pontifex, RM Thurlings… - The Journal of …, 2009 - jrheum.org
Objective. To determine whether the correlation between the mean change in disease activity
and the mean change in synovial sublining (sl) CD68 expression could be demonstrated …
and the mean change in synovial sublining (sl) CD68 expression could be demonstrated …
[HTML][HTML] Remission in psoriatic arthritis: is it possible and how can it be predicted?
…, CT Ng, G Renard, BM Lynch, E Pontifex… - Arthritis research & …, 2010 - Springer
Introduction Since remission is now possible in psoriatic arthritis (PsA) we wished to examine
remission rates in PsA patients following anti tumour necrosis factor alpha (TNFα) therapy …
remission rates in PsA patients following anti tumour necrosis factor alpha (TNFα) therapy …
Risk factors for lung cancer in patients with scleroderma: a nested case–control study
EK Pontifex, CL Hill, P Roberts-Thomson - Annals of the rheumatic …, 2007 - ard.bmj.com
Objectives: To study potential risk factors for the development of lung cancer in patients with
scleroderma and explore the chronological relationship between onset of scleroderma …
scleroderma and explore the chronological relationship between onset of scleroderma …
[HTML][HTML] Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores …
EK Pontifex, DM Gerlag, M Gogarty… - Arthritis research & …, 2011 - Springer
Introduction With the development of increasing numbers of potential therapeutic agents in
inflammatory disease comes the need for effective biomarkers to help screen for drug efficacy …
inflammatory disease comes the need for effective biomarkers to help screen for drug efficacy …
A clinically based protein discovery strategy to identify potential biomarkers of response to anti‐TNF‐α treatment of psoriatic arthritis
…, AW van Kuijk, DM Gerlag, E Pontifex… - PROTEOMICS …, 2016 - Wiley Online Library
Purpose Psoriatic arthritis (PsA) can be treated using biologic therapies targeting biomolecules
such as tumor necrosis factor alpha, interleukins (IL)‐17 and IL‐23. Although 70% PsA …
such as tumor necrosis factor alpha, interleukins (IL)‐17 and IL‐23. Although 70% PsA …
Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study
TYT Lu, CL Hill, EK Pontifex… - Rheumatology …, 2008 - Springer
Previous studies have demonstrated an increased risk of breast cancer among patients with
systemic sclerosis (scleroderma). To describe the clinical characteristics of 21 patients with …
systemic sclerosis (scleroderma). To describe the clinical characteristics of 21 patients with …
[HTML][HTML] Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
…, L Briggs, R Hijjawi, EM Shanahan, E Pontifex… - Frontiers in …, 2021 - frontiersin.org
Aims: To determine real-life biologic/targeted synthetic disease-modifying anti-rheumatic
drug (b/tsDMARD) retention rates in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and …
drug (b/tsDMARD) retention rates in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and …
Scleroderma renal crisis: observations from the South Australian Scleroderma Register
Background Scleroderma renal crisis (SRC) is a rare but feared complication with high
morbidity and mortality. Its aetiopathogenesis is unclear. Aim To investigate epidemiological, …
morbidity and mortality. Its aetiopathogenesis is unclear. Aim To investigate epidemiological, …
Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease‐modifying …
EK Pontifex, K Dissanayake, D Bursill… - International Journal of …, 2019 - Wiley Online Library
Aim Discrepancies exist between international treatment guidelines and current Australian
Pharmaceutical Benefits Scheme (PBS) criteria for funding biologic disease‐modifying …
Pharmaceutical Benefits Scheme (PBS) criteria for funding biologic disease‐modifying …
Value in performing counter-immunoelectrophoresis (CIEP) testing for extractible nuclear antigens (ENA). What is the significance of unidentified precipitin lines (UPL) …
…, L Hender, P Roberts-Thomson, E Pontifex… - …, 2024 - pathologyjournal.rcpa.edu.au
Aim: Counter-immunoelectrophoresis (CIEP) method of testing for ENA reveals unidentified
precipitin lines (UPLs). Clinical significance remains uncertain with few laboratories in …
precipitin lines (UPLs). Clinical significance remains uncertain with few laboratories in …